Sylvain Simon, PhD

Dr. Sylvain Simon is an expert in T-cell biology, focusing on how these specialized immune cells use the T-cell receptor (TCR) to recognize and eliminate diseased cells. Advances in immunotherapy have enabled scientists to repurpose T cells as powerful cancer treatments, including chimeric antigen receptor (CAR) T cells, in which genetically engineered receptors allow T cells to recognize new tumor targets. Dr. Simon aims to improve engineered T-cell therapies by making them more resistant to tumor escape mechanisms. He co-developed a novel synthetic receptor that combines the exquisite sensitivity of the TCR with the ability of CARs to recognize targets directly on the surface of cancer cells. This platform, called a chimeric T-cell receptor (ChTCR), enables a single engineered T cell to recognize multiple tumor targets simultaneously with superior sensitivity. Dr. Simon is now translating this technology toward next-generation anti-cancer T-cell therapies designed to overcome tumor variability and deliver deeper and more durable clinical responses for patients.